Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Recharge & Recaffeinate With Sidley @ JPMMonday, January 11, 2027 – Tuesday, January 12, 2027Sidley at Solana Breakpoint 2026Sunday, November 15, 2026 - Tuesday, November 17, 2026The Nonprofit Boardroom: Current Issues, Considerations, and Emerging RisksWednesday, November 4, 2026Lipp v. Mixedbread AI Addresses How a Company Can End an Advancement ObligationOctober 23, 2026Sidley Represents MidOcean Partners in Joint Venture With Idea Financial to Fund Up to US$225 Million in Small Business LoansOctober 23, 2026Sidley Represents Savillex in Its Acquisition of Entegris’ Life Sciences Fluid Management BusinessOctober 20, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory